We provide you with 20 years of free, institutional-grade data for PRME stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PRME. Explore the full financial landscape of PRME stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about PRME stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Prime Medicine, Inc.(NASDAQ:PRME) 
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime...
Website: https://www.primemedicine.com
Founded: 2019
IPO Price: $17 (Oct 20, 2022)
Full Time Employees: 150
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends